Náray-Fejes-Tóth A, Rusvai E, Fejes-Tóth G
Department of Physiology, Dartmouth Medical School, Lebanon, New Hampshire 03756.
Endocrinology. 1994 Apr;134(4):1671-5. doi: 10.1210/endo.134.4.8137730.
In addition to mineralocorticoid and glucocorticoid receptors, the kidney contains a third high affinity binding site for endogenous glucocorticoids, the type III receptor. These binding sites have been localized to the collecting duct, but their biological function has not yet been identified. We have used immunodissected rabbit cortical collecting duct (CCD) cells to further characterize these binding sites. Experiments using intact cells revealed very high levels of [3H]corticosterone (CS) binding (2.99 +/- 0.38 x 10(6) sites/cell), about 100-fold higher than the number of mineralocorticoid or glucocorticoid receptors in CCD cells. Among the two cell types of the collecting duct, principal cells, the putative targets of aldosterone, contain approximately 10 times more CS-binding sites than intercalated cells. The Kd of the binding sites for CS averaged 54.3 +/- 3.48 nM at 0 C. The relative affinity of unlabeled steroids for the binding sites is CS > carbenoxolone congruent to glycyrrhetinic acid > or = 11-dehydrocorticosterone (11-DHCS) > cortisol congruent to cortisone > deoxycorticosterone > progesterone. Synthetic glucocorticoids (dexamethasone, RU 28362, and RU 486) and aldosterone did not compete for [3H]CS binding. Based on their preferential localization to CCD cells, which are the main targets of aldosterone, we hypothesized that these CS-binding sites are involved in conferring aldosterone specificity on mineralocorticoid receptors in these cells. As 11 beta-hydroxysteroid dehydrogenase (11-OHSD) is thought to play a key role in this process, we studied the relationship between CS-binding sites and the collecting duct isoform of this enzyme (11-OHSD/CD) in purified CCD cells. Freshly isolated cells rapidly converted [3H]CS to 11-DHCS with an apparent Km of about 50 nM, a value close to the Kd of the CS-binding sites for CS in these cells. The rank order of potency of unlabeled steroids to decrease the conversion of [3H]CS to [3H]11-DHCS was identical to their relative affinity for the CS-binding sites. Also, there is a close correlation (r = 0.783; P < 0.0001) between the activity of 11-OHSD and the number of CS-binding sites in different CCD preparations. Based on the similarities between the abundant CS-binding sites and avid CS metabolism in CCD cells, we suggest that these binding sites belong to the collecting duct isoform of 11-OHSD, which, by decreasing the intracellular levels of active glucocorticoids, plays an important role in conferring aldosterone selectivity on mineralocorticoid receptors in CCD cells.
除了盐皮质激素和糖皮质激素受体外,肾脏还含有内源性糖皮质激素的第三种高亲和力结合位点,即III型受体。这些结合位点已定位到集合管,但它们的生物学功能尚未确定。我们使用免疫解剖的兔皮质集合管(CCD)细胞来进一步表征这些结合位点。使用完整细胞的实验显示[3H]皮质酮(CS)结合水平非常高(2.99±0.38×10(6)个位点/细胞),比CCD细胞中盐皮质激素或糖皮质激素受体的数量高约100倍。在集合管的两种细胞类型中,醛固酮的假定靶细胞主细胞所含的CS结合位点比闰细胞多约10倍。在0℃时,CS结合位点的Kd平均为54.3±3.48 nM。未标记类固醇对结合位点的相对亲和力顺序为CS>生胃酮≈甘草次酸>或=11-脱氢皮质酮(11-DHCS)>皮质醇≈可的松>脱氧皮质酮>孕酮。合成糖皮质激素(地塞米松、RU 28362和RU 486)和醛固酮不竞争[3H]CS结合。基于它们优先定位于醛固酮的主要靶细胞CCD细胞,我们推测这些CS结合位点参与赋予这些细胞中盐皮质激素受体醛固酮特异性。由于11β-羟类固醇脱氢酶(11-OHSD)被认为在此过程中起关键作用,我们研究了纯化的CCD细胞中CS结合位点与该酶的集合管同工型(11-OHSD/CD)之间的关系。新鲜分离的细胞迅速将[3H]CS转化为11-DHCS,表观Km约为50 nM,该值接近这些细胞中CS结合位点对CS的Kd。未标记类固醇降低[3H]CS向[3H]11-DHCS转化的效力顺序与其对CS结合位点的相对亲和力相同。此外,在不同的CCD制剂中,11-OHSD的活性与CS结合位点的数量之间存在密切相关性(r = 0.783;P < 0.0001)。基于CCD细胞中丰富的CS结合位点与活跃的CS代谢之间的相似性,我们认为这些结合位点属于11-OHSD的集合管同工型,它通过降低细胞内活性糖皮质激素的水平,在赋予CCD细胞中盐皮质激素受体醛固酮选择性方面发挥重要作用。